Abstract
Pancreatic cancer (PC), as the leading cause of cancer death worldwide, is one of the deadliest tumors with a very low 5-year survival rate. Therefore, it is urgent to seek new biomarkers of PC for more accurate and reliable treatments. To identify the differentially expressed miRNAs (DEM) in PC tissues, we performed the systematic microarray and qRT-PCR analyses. We found miR-196b was the top dysregulated DEM in PC tissues as compared with the corresponding adjacent tissues, and positively correlated with poor differentiation, tumor size, lymphatic invasion and TNM stage. Furthermore, the late apoptosis rate was significantly reduced, while the cell proliferation was increased in PANC-1 and ASPC-1 cell-lines after treatment with miR-196b mimics. The qRT-PCR and Western blot analysis demonstrated that the level of CADM1 in PANC-1 cells response to the alteration of miR-196b. Moreover, blockade of CADM1 could decrease the late apoptosis in PANC-1 cells as up-regulated by inhibition of miR-196b. Finally, luciferase report assay confirmed that CADM1 was the direct target gene of miR-196b. Overexpression of miR-196b in PC tissues can increase the late apoptosis of pancreatic cancer cells by targeting CADM1. These findings suggested miR-196b is a potential target for diagnosis and therapeutics of human pancreatic cancer.
Similar content being viewed by others
Introduction
Pancreatic cancer (PC), the 7th leading cause of cancer death worldwide, is one of the deadliest tumors with a very low 5-year survival rate (ranges from 2% to 9%)1, 2. The incidence of PC in China has been increasing rapidly during past decades3,4]. The understanding of PC has been improved, but the prognosis is still very poor, which mainly results from delayed diagnosis, lack of curative treatments, and non-specific symptoms5,6,7. Therefore, it is urgent to seek new biomarkers of PC for more accurate and reliable treatments.
Recently, there are several elements such as smoking, genetics, and environment factors have been identified as risk factors of PC5, 6, 8. However, the exact causes of PC remain unclear. MicroRNAs (miRNAs), a group of non-coding RNAs, are involved in several biological behaviors (e.g., apoptosis, proliferation, and differentiation) through inhibiting the translation or degrading the target mRNAs9, 10. Moreover, miRNAs have been reported to be involved in various diseases, especially cancers11,12,13. Several studies have reported many miRNAs (e.g., miR-21, miR-25, miR-155, and miR-210) were dysregulated in PC, but the clinical value and the exact role in pathogenesis of PC were still not clear14, 15. Therefore, systematically identifying differentially expressed miRNAs, to account for the pathogenesis of PC and be associated with clinical characteristics of PC, will provide more evidence for the diagnosis and treatment of PC.
In this study, we identified the differentially expressed miRNAs in PC tissues, find out the correlation of these miRNAs with characteristics of PC patients, and investigated the role of miR-196b in regulating apoptosis and proliferation in PANC-1 and ASPC-1 cells. Our results indicated miR-196b is a potential target to diagnosis and therapeutics of pancreatic cancer.
Results
Profiling of differentially expressed miRNAs between pancreatic cancer tissues and adjacent tissues
To find out candidate miRNAs associated with PC, 20 paired pancreatic cancer tissues and adjacent tissues were collected during resections, and were assessed by NanoString nCounter Human miRNA assay. The demographic characteristics of these patients were shown in Table 1. First, the discrete pattern of miRNAs in pancreatic cancer tissues and adjacent tissues was examined by Principal Component Analysis (PCA), and the 3-dimensional PCA (3d-PCA) plot showed that the expression profiles of miRNAs clustered into two separate groups, which was consistent with the source of tissues (Fig. 1A). In volcano plot, It was demonstrated that 39 miRNAs in pancreatic cancer tissues were significantly down-regulated, and 40 up-regulated compared with adjacent tissues (Fig. 1B, Table S1).
Next, we identified the common character among these differently expressed miRNAs by enrichment analysis. According to the database of miRNA related diseases, Human microRNA Disease Database 2 (HMDD2), we found that these DEMs were mainly associated with cancers, such as lung neoplasms, and pancreatic neoplasms (Fig. 1C). Besides, Gene Ontology (GO) annotation was also used to analyze the common functions of these DEMs. Then we found that DEMs focused in and several GO terms associated with cell proliferation, cell apoptosis, and cell death (Fig. 1D). Detailed information of enriched terms was presented in Table S2.
Validation of differentially expressed miRNAs in pancreatic cancer tissues
As shown in Table 2, we used the 5 top differentially expressed miRNAs (sorted by P value: miR-200c, miR-196b, miR-1, miR-200a, let-7b) in pancreatic cancer tissues compared with adjacent tissues in microarray as candidate miRNAs. In order to validate the difference for the expression level of these miRNAs between pancreatic cancer tissues and adjacent tissues, 80 paired pancreatic and adjacent tissues were examined (20 from the microarray cohort and 60 from the second cohort) with the demographic, clinical and pathological features presented in Table 3, were used to perform the qRT-PCR assay. Interestingly, we found that the expressions of miR-196b, miR-200a, and miR-200c were up-regulated, but miR-1 was down-regulated in pancreatic cancer tissues compared with adjacent tissues by Wilcoxon signed rank sum test (Fig. 2). However, no statistical difference of let-7b was observed between pancreatic cancer tissues and adjacent tissues. Moreover, miR-196b was observed to be the most significantly differentially expressed one among these miRNAs.
The correlation of miRNA expression and clinicopathological features of PC patients
Next, we investigated whether the levels of these differentially expressed miRNAs were associated with characteristics of PC patients. As shown in Table 4, miR-196b was found to be positively associated with poor differentiation, tumor size, lymphatic invasion and higher TNM stage, indicated its critical role in PC progression. In addition, let-7b and miR-200c were demonstrated to be positively correlated with poor differentiation, and miR-200a was positively associated with tumor size, while miR-1 was negatively correlated with poor differentiation.
MiR-196b increased late apoptosis and inhibited cell proliferation of PANC-1 and ASPC-1 cells
As MiR-196b has been observed to be a candidate biomarker in diagnosis of PC and correlated with clinicopathological features, but the function of miR-196b in PC was still unknown. Therefore, we investigated the function of miR-196b in PC cells by interference experiment. Firstly, we confirmed that the expression of miR-196b was significantly decreased after transfection with miR-196b inhibitor, and was increased after transfection with miR-196b mimics compared with each negative controls (Fig. 3). These results were also confirmed in ASPC-1 cells (Fig. S1).
Next, we assessed cell apoptosis in PANC-1 cells by two markers, FITC annexin V and propidium iodide (PI). We found that late apoptosis rate was reduced in PANC-1 cells with treatment with miR-196b mimics, and increased with miR-196b inhibitors compared with controls (Fig. 4A–F). While there was no significant change has been detected for the early apoptosis rate after transduction of miR-196b mimics or miR-196b inhibitor into PANC-1 cells. We repeat cell apoptosis assay in ASPC-1 cells and found the similar effects of miR-196b on cell apoptosis (Fig. S2A–F).
Then, We investigated whether miR-196b could regulate proliferation in PANC-1 cells, and found that the percentage of EdU positive cells was decreased in cells transfected with miR-196b inhibitors, while increased after transfected with miR-196b mimics compared with negative controls (Fig. 5A–E), indicating that miR-196b could facilitate proliferation in PANC-1 cells. The similar results were also found in ASPC-1 cells (Fig. S3A–E). Moreover, more percentage of cells was accelerated at G1 phase when treatment with miR-196b inhibitor, and which was decreased after treatment with miR-196b mimics in PANC-1 cells (Fig. 6A–E).
MiR-196b down-regulates the expression of CADM1 in PANC-1 and ASPC-1 cells
Using TargetScan analysis (http://www.targetscan.org/) (Table 5), We found 5 candidate genes (CADM1, HOXA13, IER3, MEF2C, PTGS2) targeting miR-196b. It was demonstrated that only the mRNA level of CADM1 was significantly increased in PANC-1 cells after treatment with miR-196b inhibitor, and was decreased after treatment with miR-196b mimics (Fig. 7A). These results from ASPC-1 cells confirmed the finding in PANC-1 cells. Furthermore, it suggested that HOXA13 may also response to treatment of miR-196b (Fig. S4). Consistently, miR-196b reduced the protein level of CADM1 in PANC-1 cells (Fig. 7B,C). These results suggested that CADM1 may be a direct target of miR-196b.
MiR-196b inhibited CADM1 expression by binding to its 3′UTR
To verify that CADM1 was the direct target gene of miR-196b, luciferase report assay was performed. By RNAhybrid software, we confirmed that there are two significant binding sites of miR-196b in 3′UTR of CADM1 (Fig. 8). Then, we constructed two single mutants at each binding site and one double mutant at both binding sites, labeled as MUTA, MUTB and MUTAB in luciferase report system (Fig. 8). We found that the luciferase reporter activity of CADM1 was significantly repressed after treatment with miR-196b mimic (Fig. 9, left panel). These results suggested that CADM1 was a direct target of miR-196b. Furthermore, we found that only signal from cotransfection of CADM1 with double mutant at both binding sites (MUTAB) had significant changes as compared to WT + miR-196b mimic, while no obvious difference to the WT + NC group (Fig. 9, right panel). It suggested that both of these two binding sites in 3′UTR of CADM1 were required for the effectively binding between miR-196b and CADM1.
MiR-196b regulated late apoptosis through CADM1 in PANC-1 cells
To find out whether miR-196b regulated PANC-1 cell apoptosis through CADM1, the loss-of-function experiment for CADM1 by shRNA was performed. As shown in Fig. 10, transfection of shRNA targeting CADM1 into cells suppressed the expression of CADM1, even in cell with miR-196b inhibitor. It was also demonstrated that miR-196b inhibitor decreased the expression of miR-196b in PANC-1 cells, but blockade of CADM1 did not change the level of miR-196b (Fig. 10). Intriguingly, the late apoptosis rate was decreased after transfection of shRNA targeting CADM1, and blockade of CADM1 could decrease the late apoptosis up-regulated by inhibition of miR-196b (Fig. 11A–E). These findings indicated that miR-196b regulated PANC-1 cell apoptosis through down-regulation of CADM1.
Discussion
PC has been recognized as one of the most malignant cancers worldwide, as the annual mortality of PC is almost same as the morbidity5, 6. Therefore, finding new indicators for helping the diagnosis, treatment, and prognosis of PC, is necessary. Besides, miRNAs have been found to be as tumor suppressors or promoters through regulating the expression of target genes12. In our study, we demonstrated that miR-196b expression is significantly up-regulated in PC tissues, positively correlated with differentiation grades and metastasis, and miR-196b regulates apoptosis and proliferation of PANT-1 and ASPC-1 cells via targeting CADM1.
The miR-196 family, including miR-196a and miR-196b, has been reported to be up-regulated in many cancers, such as breast cancer, leukemia, and colonic cancer16,17,18. Moreover, the level of miR-196b has been demonstrated to be increased in serum of PC patients, but the exact functions of miR-196b in PC was still unknown. In our study, we demonstrated that miR-196b expression was up-regulated in PC tissues compared with adjacent tissues, which was consistent with other cancer tissues and serum of PC patients in previous studies.
Accumulating studies have shown that miRNAs could act as biomarkers for different diseases, especially cancers, and be correlated with clinical characteristics of those patients10, 12. In this end, we next questioned whether miR-196b was correlated with characteristics of PC patients. We found miR-196b was positively associated with differentiation grades and metastasis in PC patients. Previous studies have shown that miR-196b could regulate differentiation and migration of gastric cancer cells, which may account for the results in this study19. The functions of miR-196b in cancers were also studied, and miR-196b was found to be regulating proliferation, apoptosis, differentiation and migration in different cancer cells19,20,21. In current study, miR-196b was found to promote proliferation, but inhibit apoptosis of PANC-1 and ASPC-1 cells, which was consistent with the results in other types of cancer cell in previous studies.
Our finding demonstrated that CADM1 was a target gene of miR-196b in PANC-1 cells. CADM1, which is also called as TSCL1, has been reported to be involved in cell adhesion, migration, and apoptosis22,23,24. Besides, previous study has found that CADM1 expression was down-regulated in different types of cancers, including gastric cancer, breast cancer, and lung carcinoma25,26,27. In this study, we found that miR-196b could reduce the expression of CADM1 in PANC-1 cells. Furthermore, the late apoptosis rate was decreased after transfection of shRNA targeting CADM1, and blockade of CADM1 could decrease the late apoptosis up-regulated by inhibition of miR-196b. Finally, luciferase assay confirmed that CADM1 was the target gene of miR-196b in PANC-1 cells.
In summary, our data showed that miR-196b expression is up-regulated in PC tissues, and miR-196b regulate apoptosis and proliferation of PANT-1 cells via targeting CADM1. Besides, the level of miR-196b was positively correlated with differentiation grades and metastasis in PC patients. Therefore, miR-196b might be an important biomarker in PC patients.
Methods
Clinical Specimens
Paired cancer tissues and adjacent tissues were obtained from patients recruited at Department of Gastroenterology, Zhongnan Hospital of Wuhan University, from August 2014 to July 2016, and all the patients provided written informed consent before the study protocol, with Ethical Approval provided by the Ethics Review Board of Zhongnan Hospital of Wuhan University. This study was carried out in accordance with declaration of Helsinki.
Two patient tissue cohorts were used in this study. One cohort consisted of 20 paired cancer tissues and adjacent tissues from patients with PC, which were used for miRNA microarray profiling. The other cohort with 60 paired cancer tissues and adjacent tissues from PC patients was added to the former cohort to further validate the differentially expressed miRNAs in RT-PCR. The demographic characteristics of the two groups of PC patients were described in Table 1 (20 patients) and Table 3 (80 patients).
miRNA nanostring analysis
RNA was extracted from tissue samples using TRIzol (Invitrogen, USA), and 100ng total RNA of each samples was used for analysis the expression of miRNAs using NanoString nCounter Human miRNA assay (v1) (NanoString, USA), which contains 654 probes for human miRNAs, according to manufacturer’s instructions. Global miRNA array analysis was performed by importing all data into nSolver Analysis Software v1.0 (Nanostring Technologies) and normalized to the geometric mean of the 100 miRNAs with the highest expression values. All analysis was performed using R/Bioconductor, and filtering of low-intensity signals were then conducted by requiring the mean signal intensity for tissue samples to be larger than 500.
3d PCA (Principal Components Analysis) and volcano plot were applied to describe the pattern of miRNA expression between pancreatic cancer tissues and adjacent tissues. R package limma was used to compare miRNA expression between pancreatic cancer tissues and adjacent tissues, and the differentially expressed miRNAs were required to meet criteria (absolute (log (fold change)) >1 and adjust p value < 0.05). Human microRNA Disease Database 2 (HMDD2) and Gene Ontology (GO) annotation were used to identify the relationship of the differentially expressed miRNAs with diseases and functions. The enrichment analysis of differentially expressed miRNAs was competed by R, based on the hypergeometric distribution.
Quantitative RT-PCR
For analyzing the expressions of candidate miRNAs (miR-200c (Sense: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCCAAACAC Anti-sense: ACACTCCAGCTGGGCGTCTTACCCAGCAGTGTTTGG), miR-196b (Sense: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCCCAACAA Anti-sense: ACACTCCAGCTGGGTAGGTAGTTTCCTGTTGTTGGG), miR-1 (Sense: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGATACATAC Anti-sense: ACACTCCAGCTGGGTGGAATGTAAAGAAGTATGTAT), miR-200a (Sense: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGACATCGT Anti-sense: ACACTCCAGCTGGGTAACACTGTCTGGTAACGATGT), let-7b (Sense: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAACCACA Anti-sense: ACACTCCAGCTGGGTGAGGTAGTAGGTTGTGTGGTT), RNA was reverse transcribed into cDNA using the All-in-One™ miRNA First-Strand cDNA Synthesis Kit (GeneCopoeia), and the miRNA expression was then determined by real-time PCR using the All-in-One™ miRNA qPCR Kit (GeneCopoeia). As for measurement of the expressions of mRNAs (CADM1 (Sense: TGCTGTGCTTGCTCATCATTCT Anti-sense: TCTGCGTCTGCTGCGTCAT), HOXA13 (Sense: CGCTTCAGAACTCGTTGCTTTG Anti-sense: CGGAAGAACTGGCAGTCTTTACCT), IER3 (Sense: CCAGATCCTGATGGCTGAAGAG Anti-sense: TGAGGTCCAGAGCGTAGTCC)
MEF2C (Sense: TCTGTCTGGCTTCAACACTG Anti-sense: TGGTGGTACGGTCTCTAGGA), PTGS2 (Sense: TGACCAGAGCAGGCAGATGA Anti-sense: CCAGTAGGCAGGAGAACATATAACA)), RNA was subjected to reverse transcription with 5 × All-In-One RT MasterMix kit (Applied Biological), and quantitative real-time PCR was conducted using a SYBR Green PCR kit (TaKaRa). miRNA and mRNA expression were evaluated by using the 2-ΔΔCT method with normalization to internal control, U6 (Sense: CTCGCTTCGGCAGCACA Anti-sense: AACGCTTCACGAATTTGCGT) and β-actin (Sense: ATCATGTTTGAGACCTTCAACA Anti-sense: CATCTCTTGGTCGAAGTCCA), respectively.
Cell culture and transfection
PANC-1 and ASPC-1 cells were cultured in Dulbecco’s modified Eagle medium containing 10% FBS, 1% penicillin/streptomycin, and 1% glutamine. Here, 5 nmol/L of miR-196b mimic, 50 nmol/l of miR-196b inhibitor and each negative control (Ambion, Austin, TX) were transfected into PANC-1 by using Lipofectamine RNAiMAX (Life Technologies) according to manufacturer’s instructions. The shRNA targeting CADM1 was from position + 1225 to + 1274, relative to the transcription start site, while its negative control did not match any known mammalian genomic sequence.
Cell apoptosis assay
After culture in serum-free medium for 24 hours to induce apoptosis, cells were harvested and stained with FITC annexin V and propidium iodide (PI). Cells fixed by 4% paraformaldehyde for 15 mins were used as positive control for cell apoptosis assay. Subsequently, apoptosis rate was analyzed by cytometry.
EdU cell proliferation assay
Cell-light 5-ethynyl-20-deoxyuridine (EdU) Apollo Imaging Kit (RiboBio, China) was used for measuring the cell proliferation according to manufacturer’s instructions. The percentage of EdU cells was assessed using a fluorescence microscope.
Cell cycle assay
Cells were harvested, fixed in 70% ethanol overnight, and incubated with RNaseA, followed by staining with PI in the dark for 30 minutes. Flow cytometry was used to analyze the results.
miRNA target prediction
The candidate target genes of miR-196b were predicted using TargetScan (http://www.targetscan.org/) and the miRNA-3′UTR binding sites were calculated by RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/download/tools/rnahybrid.html).
Western-blot
Cell lysates (20 g) were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis, and transferred to polyvinylidene fluoride membrane. Subsequently, the membrane was blocked, and incubated with primary and secondary antibodies. Signals were detected using the Amersham ECL Western Blotting detection system. The beta-actin and CADM1 antibodies were purchased from Abcam.
Luciferase reporter assay
3′UTR luciferase reporter assay was conducted to validate the target gene of miR-196b using the wide type and mutant 3′UTR of CADM1. The sequences of Renilla luciferase and firefly luciferase were constructed for reporter fluorescence (Rluc) and calibration fluorescence (Luc), respectively. Cells, miRNA mimic, and vectors were mixed, and cultured for 24 hours, and the luciferase activity was examined by a dual-luciferase reporter assay system.
Statistical analysis
The continuous data following normal distribution (or not) were expressed as mean ± SEM (or medium (IQR)) in this study, while categorical variables were descripted by count (percentage). Student t test and Wilcoxon sum test were used to compare two mean or median of two independent groups, while paired t test and Wilcoxon signed-rank test for paired groups. Besides, the spearman coefficients were used to identify the correlation between miRNAs and characteristics of PC patients. All statistical analysis was conducted using R, and statistical difference was set at p value < 0.05 (*), p value < 0.01(**).
References
Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136, E359–386 (2015).
Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69–90 (2011).
Guo, X. & Cui, Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas 31, 13–22 (2005).
Long, J. et al. Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett 346, 273–277 (2014).
Bosetti, C. et al. Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog 51, 3–13 (2012).
Hidalgo, M. Pancreatic cancer. N Engl J Med 362, 1605–1617 (2010).
Ryan, D. P., Hong, T. S. & Bardeesy, N. Pancreatic adenocarcinoma. N Engl J Med 371, 1039–1049 (2014).
Genkinger, J. M. et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer 129, 1708–1717 (2011).
Ambros, V. The functions of animal microRNAs. Nature 431, 350–355 (2004).
Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).
Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. Nat Rev Cancer 6, 857–866 (2006).
Esquela-Kerscher, A. & Slack, F. J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6, 259–269 (2006).
Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834–838 (2005).
Bloomston, M. et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297, 1901–1908 (2007).
Schultz, N. A. et al. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol 25, 1609–1622 (2012).
Hui, A. B. et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 89, 597–606 (2009).
Schimanski, C. C. et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol 15, 2089–2096 (2009).
Schotte, D. et al. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 23, 313–322 (2009).
Li, N. A., Wang, W., Xu, B. & Gong, H. miR-196b regulates gastric cancer cell proliferation and invasion via PI3K/AKT/mTOR signaling pathway. Oncol Lett 11, 1745–1749 (2016).
Rebucci, M. et al. miRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1. Mol Cancer 14, 79 (2015).
Cao, D. et al. MicroRNA-196b promotes cell proliferation and suppress cell differentiation in vitro. Biochem Biophys Res Commun 457, 1–6 (2015).
Liu, Z. et al. Re-expression of cell adhesion molecule inhibits growth and induces apoptosis of human pancreatic cancer cell line PANC-1. J Huazhong Univ Sci Technolog Med Sci 31, 762–767 (2011).
Sun, Z. et al. MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma. BMC Cancer 14, 616 (2014).
Yang, Z., Wang, R., Zhang, T. & Dong, X. MicroRNA-126 regulates migration and invasion of gastric cancer by targeting CADM1. Int J Clin Exp Pathol 8, 8869–8880 (2015).
McLean, M. H. & El-Omar, E. M. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol 11, 664–674 (2014).
Nakadate, Y. et al. Silencing of poly(ADP-ribose) glycohydrolase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpoint. Biochem Biophys Res Commun 441, 793–798 (2013).
Won, K. J. et al. Human Noxin is an anti-apoptotic protein in response to DNA damage of A549 non-small cell lung carcinoma. Int J Cancer 134, 2595–2604 (2014).
Author information
Authors and Affiliations
Contributions
Q.Z. and H.L.W. conceived the experiments; R.Z. and J. L. performed the experiments; Y.C. analyzed the data; S.L. and X.B.W. drafted the manuscript; M.F.H. contributed to results discussion; All authors read and approved the manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors declare that they have no competing interests.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wang, HL., Zhou, R., Liu, J. et al. MicroRNA-196b inhibits late apoptosis of pancreatic cancer cells by targeting CADM1. Sci Rep 7, 11467 (2017). https://doi.org/10.1038/s41598-017-11248-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-017-11248-3
- Springer Nature Limited